Lunai Bioworks Inc.

Lunai Bioworks Inc.

Biotechnology • Healthcare • Los Angeles, CA, United States • RENB (NCM)

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

305 918 1980 2080 Century Park East, Los Angeles, CA 90067, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Lunai Bioworks: Year-End Partnering Momentum & Stock Setup - International Business Times
International Business Times • Dec 17
Lunai Bioworks Stock Rockets 34% On AI/Zebrafish Platform Breakthrough - Nasdaq
Nasdaq • Nov 5
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - PR Newswire
PR Newswire • Dec 18
Lunai Bioworks: Stock Surge or Bubble? - timothysykes.com
timothysykes.com • Nov 25
Lunai Bioworks stock plunges after announcing 10:1 reverse split - Investing.com
Investing.com • Sep 24

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Lunai Bioworks Inc. had layoffs?
No layoff events have been recorded for Lunai Bioworks Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
What industry is Lunai Bioworks Inc. in?
Lunai Bioworks Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Lunai Bioworks Inc. a publicly traded company?
Yes, Lunai Bioworks Inc. is publicly traded under the ticker symbol RENB on the NCM. The company has a market capitalization of approximately $0.03 billion.
Where is Lunai Bioworks Inc. headquartered?
Lunai Bioworks Inc. is headquartered in Los Angeles, CA, United States at 2080 Century Park East, Los Angeles, CA 90067, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.